On April 12, 2024, AEON Biopharma, Inc. closed the transaction. The company issued one senior secured convertible note in the principal amount of $10,000,000 for a gross proceeds $10,000,000 in its final tranche. The Convertible Note contains customary events of default, accrues interest at an annual rate of 15.79% and has a maturity date of April 12, 2027, unless earlier repurchased, converted or redeemed in accordance with its terms prior to such date.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -8.33% | -6.10% | -78.61% |
May. 16 | AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024 | CI |
May. 16 | AEON Biopharma, Inc. Announces Executive Changes | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
107,200 KRW | -1.65% | +0.28% | 910M | ||
1.54 USD | -8.33% | -6.10% | 65.73M | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-78.61% | 65.73M | |
+18.82% | 125B | |
+13.86% | 108B | |
-7.53% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-14.04% | 16.37B | |
+2.04% | 13.58B | |
+27.72% | 11.66B |
- Stock Market
- Equities
- AEON Stock
- News AEON Biopharma, Inc.
- AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd